Dejan Landup
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dejan Landup has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth Van Dril
University of Illinois Chicago Herbert M. And Carol H. Retzky College of Pharmacy Chicago Illinois USA
2 shared publications - Charlotte Bolch
Midwestern University
1 shared publication - Christie Schumacher
Midwestern University College of Pharmacy, Downers Grove Campus Downers Grove Illinois USA
1 shared publication - Emily Hanners Dunn
University of Illinois Hospital & Health Sciences System Chicago Illinois USA
1 shared publication - Robert J. DiDomenico
Department of Pharmacy Practice University of Illinois Chicago Retzky College of Pharmacy Chicago Illinois USA
1 shared publication - Sara Salama
Advocate Health Orland Park Illinois USA
1 shared publication
Latest Publications
- 14 May 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (6) , e70156
Factors That Influence Blood Pressure Changes With the Use of Sodium‐Glucose Cotransporter 2 Inhibitors in People With Type 2 Diabetes
Study Objective: Multiple clinical trials have reported variable reductions in blood pressure with sodium–glucose cotransporter 2 (SGLT2) inhibitors. Given the variability in the magnitude of blood pressure reduction observed across studies, there is interest in understanding how patient‐specific factors influence the blood pressure‐lowering effects of SGLT2 inhibitors. The primary objective of this study was to evaluate factors that influence blood pressure changes in people with type 2 diabetes when an SGLT2 inhibitor is initiated. Design: Multicenter retrospective cohort chart review. Data Source: Patients were selected through an electronic medical record‐generated report between January 1, 2013, and September 30, 2019. Patients: Adults (≥ 18 years) receiving care within Advocate Medical Group were included if they had a documented diagnosis of type 2 diabetes and had been prescribed one of four SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin) for at least 7 days. Results: In 1,422 patients, mean systolic blood pressure (SBP) decreased by 4.1 mmHg (range −58.7 to 58.0), and mean diastolic blood pressure (DBP) decreased by 2.1 mmHg (range −44.7 to 29.0) after SGLT2 inhibitor initiation. Significant blood pressure reductions occurred only in patients with elevated baseline blood pressure, with greater declines at higher baseline pressures ( p < 0.001). Patients with baseline SBP > 160 mmHg showed a mean reduction of 26.7 mmHg, whereas those with SBP < 120 mmHg had a mean increase of 6.1 mmHg. DBP followed a similar pattern: Individuals with baseline DBP > 100 mmHg had a mean reduction of 16.0 mmHg, whereas those with DBP < 60 mmHg experienced a mean increase of 10.7 mmHg. Conclusion: Blood pressure responses to SGLT2 inhibitors were driven by baseline blood pressure, with the greatest reductions observed in patients with elevated blood pressure at initiation. Individuals with lower starting pressures showed minimal change or slight increases, indicating a normalizing effect rather than uniform blood pressure lowering with initiation of SGLT2 inhibitors. These findings support incorporating baseline blood pressure into treatment selection to optimize cardiovascular risk management in patients with type 2 diabetes.
- 14 May 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (6) , e70156
Factors That Influence Blood Pressure Changes With the Use of Sodium‐Glucose Cotransporter 2 Inhibitors in People With Type 2 Diabetes
Study Objective: Multiple clinical trials have reported variable reductions in blood pressure with sodium–glucose cotransporter 2 (SGLT2) inhibitors. Given the variability in the magnitude of blood pressure reduction observed across studies, there is interest in understanding how patient‐specific factors influence the blood pressure‐lowering effects of SGLT2 inhibitors. The primary objective of this study was to evaluate factors that influence blood pressure changes in people with type 2 diabetes when an SGLT2 inhibitor is initiated. Design: Multicenter retrospective cohort chart review. Data Source: Patients were selected through an electronic medical record‐generated report between January 1, 2013, and September 30, 2019. Patients: Adults (≥ 18 years) receiving care within Advocate Medical Group were included if they had a documented diagnosis of type 2 diabetes and had been prescribed one of four SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin) for at least 7 days. Results: In 1,422 patients, mean systolic blood pressure (SBP) decreased by 4.1 mmHg (range −58.7 to 58.0), and mean diastolic blood pressure (DBP) decreased by 2.1 mmHg (range −44.7 to 29.0) after SGLT2 inhibitor initiation. Significant blood pressure reductions occurred only in patients with elevated baseline blood pressure, with greater declines at higher baseline pressures ( p < 0.001). Patients with baseline SBP > 160 mmHg showed a mean reduction of 26.7 mmHg, whereas those with SBP < 120 mmHg had a mean increase of 6.1 mmHg. DBP followed a similar pattern: Individuals with baseline DBP > 100 mmHg had a mean reduction of 16.0 mmHg, whereas those with DBP < 60 mmHg experienced a mean increase of 10.7 mmHg. Conclusion: Blood pressure responses to SGLT2 inhibitors were driven by baseline blood pressure, with the greatest reductions observed in patients with elevated blood pressure at initiation. Individuals with lower starting pressures showed minimal change or slight increases, indicating a normalizing effect rather than uniform blood pressure lowering with initiation of SGLT2 inhibitors. These findings support incorporating baseline blood pressure into treatment selection to optimize cardiovascular risk management in patients with type 2 diabetes.
- 5 February 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (2) , e70181
The Cost Conundrum: Pharmacists at the Crossroads of Evidence and Affordability
- 5 February 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (2) , e70181
The Cost Conundrum: Pharmacists at the Crossroads of Evidence and Affordability